Prasugrel Monotherapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Platinum-Chromium Everolimus Eluting Stent for Japanese Patients With Chronic Coronary Syndrome (ASET-JAPAN)Takashi Muramatsu, Yoshinobu Onuma, Shinichiro Masuda et al.|Circulation Journal|2023Cited by 32
Preprocedural physiological assessment of coronary disease patterns to predict haemodynamic outcomes post-PCINozomi Kotoku, Patrick W. Serruys, Kai Ninomiya et al.|EuroIntervention|2023Cited by 16
The Utility of the SYNTAX Score II and SYNTAX Score 2020 for Identifying Patients with Three-Vessel Disease Eligible for Percutaneous Coronary Intervention in the Multivessel TALENT Trial: A Prospective Pilot ExperienceKai Ninomiya, Yoshinobu Onuma, Helge Möllmann et al.|Reviews in Cardiovascular Medicine|2022Cited by 5
Geographic disparity of pathophysiological coronary artery disease characteristics: Insights from ASET trialsNozomi Kotoku, Patrick W. Serruys, Kai Ninomiya et al.|International Journal of Cardiology|2024Cited by 4
CRT-100.33 A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) in Brazil and Japan: Synergy Stent with Prasugrel Monotherapy Without AspirinYoshinobu Onuma, Patrick W. Serruys, Shinichiro Masuda et al.|JACC: Cardiovascular Interventions|2023Cited by 1